4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $537646 | $4M | 172.6% | -372.0% | — | $2M | $9M |
| 2024 | $1M | $1M | 232.1% | 144.9% | -$802943 | $1M | $7M |
| 2023 | — | $969752 | — | — | -$917632 | $787860 | $1M |
| 2022 | — | $244587 | — | — | -$684059 | — | $293511 |
How the market has priced HAO against its own fundamentals since 2024-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, Haoxi Health Technology Ltd's revenue has declined 54.6% per year, and net income grown 151.2% per year. These are computed facts, not advice.
As of FY2025, Haoxi Health Technology Ltd reported $2M of total debt against $9M of cash.
In FY2025, gross margin was 172.6%, operating margin -372.0%, and net margin 721.0%.
As of Jun '26, Haoxi Health Technology Ltd traded at a price-to-earnings ratio of about 2.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.